
Hercules Capital
Description
Hercules Capital stands as a prominent specialty finance company and the leading publicly traded business development company (BDC) focused on providing venture debt financing to innovative, high-growth companies. Headquartered in San Mateo, California, the firm primarily targets companies across the technology, life sciences, and sustainable and renewable technology sectors. Unlike traditional venture capital firms that primarily offer equity, Hercules Capital provides a crucial alternative financing solution, enabling companies to secure capital without significant equity dilution, which is particularly attractive for founders looking to retain ownership.
The firm's investment strategy centers on offering flexible debt facilities tailored to the specific needs of its portfolio companies, spanning various stages from venture-backed startups to more mature, pre-IPO companies. Hercules Capital typically provides initial commitments ranging from approximately $5 million to $50 million, though their capacity can extend significantly higher for larger, later-stage enterprises. Their financing solutions often include warrants or equity participation, aligning their interests with the long-term success of their portfolio companies while primarily generating returns through interest income.
Since its inception, Hercules Capital has demonstrated significant scale and impact within the venture ecosystem. The firm has committed over $18 billion in capital to more than 600 companies, showcasing its extensive reach and experience in supporting a diverse range of innovative businesses. As of late 2023, Hercules Capital managed total assets of approximately $4.0 billion, underscoring its robust financial position and continued ability to deploy substantial capital. This makes them a critical partner for companies seeking non-dilutive growth capital, complementing traditional equity funding rounds.
Investor Profile
Hercules Capital has backed more than 263 startups, with 14 new investments in the last 12 months alone. The firm has led 131 rounds, about 50% of its total and boasts 152 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Debt Financing, Post Ipo Debt, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States, United Kingdom, Canada.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Led 10 rounds in the past year.
- Typical check size: $5M – $50M.
Stage Focus
- Debt Financing (38%)
- Post Ipo Debt (36%)
- Series Unknown (11%)
- Series E (3%)
- Series C (3%)
- Series D (3%)
- Post Ipo Equity (2%)
- Series B (1%)
- Series F (1%)
- Private Equity (1%)
Country Focus
- United States (86%)
- United Kingdom (4%)
- Canada (3%)
- Switzerland (1%)
- Israel (1%)
- Germany (1%)
- The Netherlands (1%)
- Australia (1%)
- Spain (1%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Medical
- Software
- Therapeutics
- Manufacturing
- Medical Device
- Biopharma
- Enterprise Software
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.